Podcasts about Chemotherapy

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

- Broadcast News Introduction and Upcoming Segments (0:00) - AI Advancements and Their Impact on Jobs (0:45) - Breaking News: Trump-China Trade Deal and Its Implications (2:46) - Pakistan-India Cyber War and Its Potential Escalation (9:55) - Power Grid Vulnerabilities and Preparedness (13:36) - Crypto Wallets and the Importance of Self-Custody (19:04) - AI Capabilities and Their Implications for Human Jobs (25:14) - The Role of Enoch AI in Empowering Users (59:30) - The War on Human Cognition and Its Vectors (1:05:29) - Strategies for Protecting Cognitive Function (1:21:34) - Chemotherapy and Cognitive Impairment (1:21:56) - Natural Light and Sun Exposure (1:25:06) - Media and Information Warfare (1:30:33) - Societal and Behavioral Factors (1:33:37) - Defending Against Environmental Toxins (1:41:05) - Nutritional and Dietary Factors (1:47:00) - Pharmaceutical and Medical Warfare (1:49:22) - EMF Exposure and Technological Risks (1:59:51) - Information Warfare and Censorship (2:02:12) - Societal and Behavioral Factors (2:11:11) - Zionist and Chinese Strategic Moves in the Middle East (2:25:45) - Trump's Arrogance and Military Presence in Panama (2:26:04) - China's Influence and Economic Strategy in Panama (2:26:21) - Strategic Importance of the Panama Canal (2:52:23) - Strait of Hormuz and Global Energy Supply (3:06:20) - US-China Trade War and Economic Implications (3:14:03) - Anthropological Warfare and Cultural Resilience (3:14:21) - Migration and Demographic Warfare (3:22:15) - Global Economic and Political Dynamics (3:28:51) - Future Strategic Moves and Predictions (3:33:17) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Episode Summary: In the beatitudes, Jesus paints a portrait of spiritual vitality and health into which Christ's kingdom members are being transformed. But at the root of that transformation process is cutting out the cancer of sin. Such excision of sin requires both confessing it, the first beatitude, and grieving over it, the second beatitude. The combination of these two attitudes is called repentance. The problem is that Christians can be lured into a kind of shallow, incomplete repentance that is destructive. It might be compared to surgery to remove the cancerous tumor that misses part of the tumor. Paul calls it “worldly sorrow that leads to death.” In contrast, says Paul, is “godly sorrow leading to repentance.” This godly sorrow corresponds to getting all the tumor and then using chemotherapy to destroy what is microscopic and missed. This kind of sorrow is the heart attitude Jesus refers to in the second beatitude. “Blessed are those who mourn, for they shall be comforted.” It is an attitude that is exhibited by David. It is described in unmistakable detail in Psalm 51, which he wrote after being confronted with his sin of adultery with Bathsheba and murder of her husband, Uriah. It is chemotherapy for sin.For Further Prayerful Thought: How would you defend the argument that confessing our sins is not enough; we need to grieve over them.What most stood out to you about David's confession of his sin in Psalm 51?How does Jesus' claim to be the messianic suffering servant whose ministry is described in Isaiah 61 show that his mission goes beyond going to the cross so we could be forgiven for our sins? What clues in Isaiah 61 and the second beatitude point to Jesus' current work of restoration—fixing whatever was broken by sin?For the printed version of this message click here.For a summary of topics addressed by podcast series, click here.For FREE downloadable studies on men's issues click here.To make an online contribution to enable others to hear about the podcast: (Click link and scroll down to bottom left)

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Chemotherapy not only changes how your brain thinks, it also impacts your emotional regulation. How do you manage brain fog and chemo rage? Listen to learn about ways to harness this emotional energy and channel it in productive ways.  https://bit.ly/4iWTmpMIn this Episode:01:39 - Streaming Series Review:  Adolescence05:22 - New Jersey and Coconut Cream Pie06:23 - What Does American Medical Debt Look Like?10:17 - Chemo Rage: What it is and What Causes it17:21 - How to Cope with Chemo Rage20:34 - How to Help a Loved One with Chemo Rage24:57 - Poem, "Speak the Cancer"26:20 - OutroSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

On this week's episode, Dr. Cox struggles to support his best friend through Chemotherapy. In the real world, Zach and Donald are joined by Brendan Fraser! Brendan reveals his love of photography, that time he worked with Mos Def, and what it's like to be stopped by Scrubs fans nearly 20 years after his first appearance on the show. See omnystudio.com/listener for privacy information.

The woman details her chemotherapy treatment plan, which includes six rounds of chemotherapy every three weeks, followed by surgery and a year of immunotherapy.

 How does chemotherapy work and why does it cause side effects? We answer these questions and more in this episode as we continue our series about cancer with a discussion about chemotherapy. https://bit.ly/42HvhykIn this Episode:03:31 - Travel: Rhode Island and Clam Cakes04:35 - Anna Quindlen - We Need to "Get a Life"08:45 - Chemotherapy Overview: How it works, Cycles, Port12:19 - Types of Chemotherapy Drugs15:35 - Apoptosis and Chemo Success17:04 - Side Effects of Chemotherapy18:02 - Discussion - "How Long Has Chemo Been in Use?"21:41 - Jeena R. Papaadi, "The Person in the Bed"24:51 - OutroRelated Episodes:S6E4: Understanding Cancer Treatment Options: ImmunotherapyS6E3: Understanding Cancer Treatment Options: Radiation TherapyS6E2: Understanding Cancer Treatment Options: SurgeryS5E52: Cancer Gone Wild – Learn All About MetastasisS5E45: Why Does Cancer Exist? Empower Yourself With UnderstandingS5E46: “Why Do I Have Cancer?” Kismet, Chastisement or Coincidence?S5E47: MythBusters – Cancer Edition; Clarifying Common Cancer Myths & MisconceptionsS5E48: How to Read a CT Scan Report – Learn the Sections Relevant to Your DiagnosisS5E49: Are there Miracle Cures for Cancer? With Dr. Jeanna FordS5E50: What is Meant by Cancer Staging? Learn the Language of a Cancer Diagnosis#cancer #cancertreatment #cancertreatmentoptions #chemotherapyeducation #palliativecare #cancereducation #cancerresources #sideeffects #everydayisagift #everyonediesSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

In this episode, our guest Sharon, from Scotland, shares her powerful journey of overcoming stage 3 ovarian cancer. After a difficult experience with chemotherapy, Sharon turned to cannabis oil—and believes it played a key role in her survival. Now cancer-free and devoted to helping others, she opens up about the stigma, the scams, the healing, and the deeper personal transformation that followed.This is a story of fierce determination, intuitive self-advocacy, and the healing potential of plant medicine.00:38 – Introduction: Ovarian cancer stats and global impact01:52 – Sharon's first symptoms and long path to diagnosis03:02 – The moment she was told she had cancer04:46 – Mental health, grief, and personal transformation06:56 – Relationships lost and reshaped after diagnosis07:10 – Chemotherapy: side effects and regret08:39 – Finding cannabis oil and getting scammed10:29 – The importance of trusted sources and education11:12 – Taking oil before, during, and after chemo13:40 – “I'd be dead without it”—how cannabis helped her survive17:39 – Continued use of oil and current regimen19:31 – Managing chemo-induced neuropathy21:40 – Family dynamics and their view of cannabis23:12 – Survivor's guilt and a desire to help others28:01 – Nutrition, self-care, and guiding others toward options30:57 – Her advice to women newly diagnosed with ovarian cancer34:39 – Final thoughts and gratitude Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

You cannot know Jesus in any real depth unless you share in his sufferings. -------- Thank you for listening! Your support of Joni and Friends helps make this show possible.     Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org   Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

In this episode, Dr. Jake breaks down the truth about Vitamin C and chemotherapy, debunking myths and revealing how high-dose IV Vitamin C can actually enhance cancer treatment. Dr. Jake, a naturopathic medical doctor and integrative physician, shares insights on how this natural and non-toxic treatment and whether or not it actually reduces chemotherapy side effects like fatigue, nausea, and neuropathy, without compromising its effectiveness. And does it work best by integrating such protocols with conventional treatments for optimal results? Doctor Jake speaks on all of this. If you're curious about root cause solutions and integrative health strategies, Dr. Jake's got you on that! Dive into integrative healing approaches and get empowered to improve your well-being. Ready for Vitamin C infusions? Contact Dr Jake at https://integrativemedica.com#vitaminc #Chemotherapy #NaturalHealing #IntegrativeHealth

Former NFL star Rick Upchurch seemed to be in good health, but in 2010, he began to experience night sweats, fatigue and aches and pains.  He saw his doctor, who ordered blood work.  The test results revealed his white blood cell count was very high, and his general practitioner gave him the address of another doctor to see.   Rick and his wife were shocked to learn the doctor they had been told to see was an oncologist.  That doctor called for a bone marrow biopsy, which confirmed Rick had chronic myelogenous leukemia, a rare form of blood cancer that is tied to a genetic mutation called Philadelphia chromosome.   The onocologist prescribed a chemotherapy regimen for Rick, but to some degree he was relieved to learn that it would be a regimen of oral chemotherapy.  The medication was known as tasigna, which also goes by the name of nilotinib.  Rick had to take these pills three times a day, which he still has to do, and will have to do for the rest of his life.   Rick Upchurch's chemotherapy regimen led to survivorship, but again, he has to take the tasigna three times a day, something he will need to do for the rest of his life.  He has his good days and bad days.   On the bad days, he still experiences the fatigue, night sweats, achy muscles and joints; and he sometimes has diarrhea, as his body has a tough time processing the tasigna.  However, he is grateful to be alive and grateful for the good days, in which he can lift weights, get on the elliptical and go for walks.   Rick and his wife, Donna, also engage in a number of activities that support children with cancer.

I'm a 70-year-old woman with hip arthritis. Any recommendations?A treatment on the horizon for high Lipoprotein (a)?After chemotherapy to help shrink a tumor near my husband's spine, he now has numbness and neuropathy in his legsAnother study implicates meat, and now poultry and fish, in causing cardiovascular diseaseWhat do you think of Consumer Lab's recommendations on supplements?I take CoQ10, but I just heard about PQQ. What are your thoughts?

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness  https://www.katiedeming.com/prolonged-water-fasting/What would you do first if you received a cancer diagnosis? Dr. Katie shares why a 30-day water fast would be her first response to cancer—and why many health experts like Dr. Mark Hyman and Dr. Jason Fung agree. Dr. Deming presents six compelling reasons why prolonged water fasting creates powerful healing opportunities for cancer patients. She explains how cancer as a metabolic condition responds to fasting, why it helps detoxify the body on physical, emotional and mental levels, and how it flips the script on cancer's parasitic nature. You'll hear real examples of clients who experienced profound healing through this approach, including one whose brain tumor completely disappeared.Key Takeaways:How to shut down your cancer's fuel sourceLetting go of years of toxic buildupWhat a stronger gut means to youClarity comes when the noise inside quiets downDr. Deming transparently shares her journey from skepticism to conviction based on client outcomes she never witnessed in traditional medicine. Her honest assessment of water fasting challenges common medical assumptions while offering hope to those seeking alternatives or complementary approaches.Dr. Deming explains the science behind water fasting while acknowledging safety considerations and proper supervision. Listen and expand your understanding of what's possible when we create the right conditions for our bodies to heal themselves naturally.Send us a text with your question (include your phone number) Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatie Don't Face Cancer Alone"The 6 Pillars of Healing Cancer" workshop series provides you valuable insights and strategies to support your healing journey - Click Here to Enroll MORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/6 Pillars of Healing Cancer Workshop Series - Click Here to EnrollWork with Dr. Katie: www.katiedeming.comFollow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Take a Deeper Dive into Your Healing Journey: Dr. Katie Deming's Linkedin Here Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER:The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose...

Jill opened the show talking about her new Rebelle Rally team. Listen in for details. Tom shared some information about a not-for-profit organization that packages sundry products for patients undergoing Chemotherapy. The packages include items to help recipients deal with chemo side effects, including loss of taste, dry skin, and dehydration. You can check out Lemons of Love at lemonsoflove.org. The hosts went to discuss the Cybertruck. The polarizing Tesla pickup is no longer being accepted in trade by Tesla, a thing which will likely impact resale value. Also, Tesla has introduced a new, less expensive Cybertruck trim level, which may lure some shoppers back into showrooms. Tom noted the addition of a more affordable trim level to the GMC Sierra EV lineup. The new model lowers the cost of entry for a Sierra EV considerably. Still in the first segment, Jill and Tom talked about Jeff Bezos' new EV startup Slate Auto. The new company is gearing up to produce small, $25,000 electric pickup trucks meant to be customized by the end user. Production begins as early as late next year. In the second segment, the hosts welcome veteran auto journalist Gary Witzenburg to the show. Gary talked about a pair of articles he recently wrote, both about 2-seat Pontiacs. The first, which appeared recently in Collectible Automobile, covered the Fiero. The latter, which appeared on the Haggerty website, covered the brand's Solstice small sports car. Listen in for fascinating insights into both cars. In the last segment, Jill is subjected to Tom's “Sixty More Seconds” quiz. How did she do? Listen in. 

Editor in Chief Dr. Sue Yom hosts a discussion on the role of radiation for gallbladder cancer, as it is managed in India versus the U.S. Guests are Section Editor Dr. Michael Chuong, Vice Chair and Medical Director of Radiation Oncology at Miami Cancer Institute, and Dr. Sushma Agrawal, Professor from the Department of Radiotherapy at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lacknow, India, RACE-GB Principal Investigator, and first author of the primary trial report, A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB Study.

“It's been known for quite a while that [KRAS] is a mutation that leads to cancer development, but for really over four decades, researchers couldn't figure out a way to target it. And so, it was often considered something that was undruggable. But all of this changed recently. So about four years ago, in 2021, we had the approval of the first KRAS inhibitor. So it's specifically a KRAS G12C inhibitor known as sotorasib,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the KRAS inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 11, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to KRAS inhibitors used for cancer treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Cancer Symptom Management Basics series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer Oncology Drug Reference Sheet: Adagrasib Oncology Drug Reference Sheet: Sotorasib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS course: Safe Handling Basics ONS video: What is the role of the KRAS biomarker in NSCLC? ONS Targeted Therapy Huddle Card ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets Lumakras® (sotorasib) manufacturer website Krazati® (adagrasib) manufacturer website UpToDate Lexidrug (formerly Lexicomp) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “If we look at specifically non-small cell lung cancer, this KRAS mutation is one of the most frequently detected cancer drivers or driver mutations. It's thought that about a quarter of cases of non-small cell lung cancer have this KRAS mutation, and it's usually a specific amino acid substitution that we see in non-small cell lung cancer, so what's known as KRAS G12C mutation.” TS 2:31 “Both of these agents, sotorasib and adagrasib, have the same mechanism of action. They bind to a pocket, very specifically on the KRAS G12C protein, and they lock it in an inactive state so that it can't cause that downstream uncontrolled signaling to happen. So they're kind of shutting down the signaling, and therefore you don't get that uncontrolled cell growth and proliferation.” TS 4:27 “Another big difference to point out, and one that is often used in clinical practice to differentiate when to use these agents, is specifically adagrasib is known to have activity in patients with metastatic non-small cell lung cancer that have active brain metastases. In the clinical trial, they included patients with active brain metastases, and they found that this drug has great [central nervous system] penetration. And so it may be considered the agent of choice in patients with brain metastases.” TS 7:19 “Other considerations—I think one of the big ones—is that there are a lot of drug interactions. Just specifically calling one out that I think is pretty impactful, is sotorasib has an interaction with acid-suppressing medications. So there is the recommendation to avoid [proton pump inhibitors] and H2 antagonists in patients receiving sotorasib. They can take antacids, but you would need to space those out from their dose of sotorasib.” TS 14:14 “This needs to be a collaborative endeavor to make sure these patients are monitored appropriately. We are putting a lot of responsibility on the patients with all of this. So, again, completely administered generally in the home setting, a lot of monitoring, a lot of adverse effects, need for reporting and management—so there's a lot happening here. And it takes a team to accomplish this and to do it right. And I firmly believe that this is often a collaborative effort between our pharmacy and oncology nursing teams to make this happen. Working together to ensure outreach to patients—I think that patients are often more successful with these medications with early identification of toxicities when we're doing scheduled outreach.” TS 19:44

In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.

“There have been many changes since the '70s that have shaped the nurse's role in administering chemo, and in supporting patients. The major change early on was the transition from that of nurses mixing chemo to that of pharmacists. Regulatory agencies like NIOSH and OSHA defined chemotherapy as hazardous drugs, and professional organizations became involved, leading to the publication of the joint ASCO and ONS Standards of Safe Handling,” ONS member Scarlott Mueller, MPH, RN, FAAN, secretary of the American Cancer Society Cancer Action Network Board and member of the Oncology Nursing Foundation Capital Campaign Cabinet, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, ONS member and chair of the ONS 50th Anniversary Committee during a conversation about the evolution of chemotherapy treatment. Along with Mueller, Burbage spoke with John Hillson, DNP, NP, Mary Anderson, BSN, RN, OCN®, and Kathleen Shannon-Dorcy, PhD, RN, FAAN, about the changes in radiation, oral chemotherapy, and cellular therapy treatments they have witnessed during their careers. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: 50th anniversary series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 59: Blood and Marrow Transplant Nursing Episode 16: Navigating the Challenges of Oral Chemotherapy ONS Voice article:Safe Handling—We've Come a Long Way, Baby! ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (second edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: ONS Hematopoietic Stem Cell Transplantation™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Safe Handling Basics Oral Anticancer Medication Toolkit Oral Anticancer Medication Care Compass Patient education guides created as a collaboration between ONS, HOPA, NCODA, and the Association of Community Cancer Centers: IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Hillson: “I remember as a new grad, from back in '98, walking up to the oncology floor. We had patients with pink labels on the chart and that was the radiation oncology service. I hadn't heard of such a thing before. … I'd gone through nursing school and hospital orientation and unit orientation without ever hearing of these therapies. At the time, both the management and the union had no interest in specialist nurses, and the really weren't any books that were targeting the role. And it was very isolating and frightening. I was very glad to find ONS when I moved to the U.S. Right now, the Oncology Nursing Society Manual for Radiation Oncology, Nursing Practice, and Education, it's in its fifth edition and a sixth is underway. There's nothing else like it. Most books are very much geared towards other professions.” TS 5:34 Mueller: “We mixed our chemo in a very small medication room on the unit, under a horizontal laminar flow hood, which we later discovered should have been a vertical laminar flow hood. Initially, we did not use any personal protective equipment. I remember mixing drugs like bleomycin and getting a little spray that from the vial onto my face. And to this day, I still have a few facial blemishes from that.” TS 14:28 Anderson: “As the increasing number of these actionable mutations continue to grow, so will the number of oral anticancer medications that patients are going to be taking. And we are already seeing that there's multiple combination regimens and complex schedules that the patients have to take. So this role the oral oncolytic nurse and the nursing role, like you said, it cannot be owned by one individual or discipline. So it's not a pharmacist; the pharmacies aren't owning this. The nurses are not owning this. It takes a village.” TS 32:12 Shannon-Dorcy: Then as immunotherapy comes into the picture, we start to learn about [cytokine release syndrome]. All of a sudden, we had no concept that this was a deadly consequence. ONS was on the front lines, convening people across the country together so we could speak to the investigative work with science and find ways that we could intervene, how we can look for signs of it early on with handwriting testing.” TS 39:58

Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care

What if your skin could do more than protect you? In this thought-provoking episode of The Technology of Beauty, Dr. Grant Stevens sits down with Ryan Beal, the CEO of Dyve Biosciences, to explore how transcutaneous drug delivery is poised to reshape both the aesthetics industry and the field of oncology. With Dyve's pioneering platform, molecules once limited to injections or oral delivery are now being driven through the skin — offering a powerful new frontier in treatment possibilities.Ryan walks us through Dyve's surprising evolution from skincare applications and elite athletic performance enhancement to its most ambitious moonshots: noninvasive fat reduction and improving chemotherapy effectiveness through targeted pH modulation.This episode also takes a personal turn, as Ryan opens up about his recent battle with cancer—a diagnosis that came just months after speaking about oncology research on a previous episode. Now a survivor, Ryan shares how his company's technology played a direct role in his treatment, potentially boosting the efficacy of his own chemotherapy regimen. It's a powerful testament to the impact of innovation when professional purpose and personal experience collide.From fat-melting topicals to transdermal neurotoxins and tumor microenvironment alkalinization, Ryan Beal offers an inspiring look at how Dyve Biosciences is transforming medicine one molecule—and one patient—at a time. Don't miss this candid, cutting-edge conversation about the future of drug delivery and the deeply human stories behind biotech breakthroughs on the latest episode of The Technology of Beauty.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/

Karen shares how a friend's breast cancer diagnosis became a powerful example of self-advocacy in action. From discovering she didn't need chemotherapy after requesting additional testing, to researching scalp cooling treatments and skin protection during radiation, this story highlights how knowledge and persistence can lead to better care. Visit our website itchyandbitchy.com to read blog posts on the many topics we have covered on the show.

What John Morley originally thought was a urinary tract infection turned out to be a diagnosis of bladder cancer.  At first, he was told it was a mild form of the disease.  Then the diagnosis was upgraded to T2 Muscle Invasive Bladder Cancer, requiring a radical cystectomy meaning he would need to get his bladder removed.  His care team next told John he would also have to get his prostate taken out.  Next a mass was detected on his spleen, which meant that it, too, would have to be removed.  Treatment and recovery were tough, but he now urinates into a bag known as an ileal conduit, has become acclimated to it and leads a healthy lifestyle.   John Morley of Haymarket, Virginia is a Navy veteran who enjoyed scuba diving, hiking and other outdoor activities when in late 2021, he noticed blood in his urine.  He sought medical attention with his primary care physician, who upon learning of John's symptoms, referred him to a urologist.  The urologist called for cystoscopy, a procedure in which a camera is inserted in the patient's urethra, and based on its results, said a biopsy would be needed.   John received a blend of bad and good news.  He was told he had bladder cancer, but because it was T1 Non-Muscle Invasive Bladder Cancer, the cancer had not spread from his bladder.  John and his wife felt like celebrating and went out to dinner.   However, a short time later, John Morley was called back into the doctor's office.  He and his wife were told a followup check of his pathology report showed his cancer had been upgraded to T2 Muscle Invasive Bladder Cancer.  Not only did this mean John would have to undergo a radical cystectomy to remove his bladder, but the procedure would have to be preceded by two or three months of chemotherapy, a regimen that would include cisplatin and gemacitabine.   As he wondered what life would be like without a bladder, the news for John got worse.  He was told he would have to undergo a prostatectomy for the removal of his prostate.  Then a mass was detected in his spleen, and the spleen would have come out as well, all three in the same surgery.   The multi-faceted surgery was a success, but John had to decide how he was going to urinate.  Over two other options, he chose an ileal conduit.  It was attached to his stomach, close to his navel.  The urine drained into a urostomy bag.   Following the operation, John relied on walking to help him slowly regain his strength.  He has a good command of his use of the urostomy bag, and though it wasn't what he enjoyed pre-diagnosis, John Morley has returned to a healthy lifestyle that includes scuba diving.   Additional Resources:   Support Group: The Bladder Cancer Advocacy Group: https://www.bcan.org   John Website: https://www.beatbladdercancer.org            

“And so you have different kinds of hazards with the drugs that you're using. That means that in the past, when a lot of oncology drugs, antineoplastic drugs used to treat cancer would have been added, you may see that a lot of oncology drugs either weren't added or they're added in a different place on the list than they were in the past. That's due to some of the restructuring of the list we'll probably talk about later,” Jerald L. Ovesen, PhD, pharmacologist at the National Institute for Occupational Safety and Health (NIOSH) and Centers for Disease Control and Prevention, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the latest update to the NIOSH list of hazardous drugs.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Episode Notes   NCPD contact hours are not available for this episode.  ONS Podcast™ episodes: Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs  Episode 142: The How-To of Home Infusions Episode 68: Empowering Healthcare Workers to Handle Hazardous Drugs Episode 53: Home Care Nursing for Patients With Cancer ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE  NIOSH Releases Its 2024 List of Hazardous Drugs  No Place Like It: Home Care for Patients With Cancer  What Is ONS's Stance on Handling Chemotherapy While Pregnant, Breastfeeding, or Trying to Conceive?  What You Wear Matters When It Comes to Safety  ONS book: Safe Handling of Hazardous Drugs (Fourth Edition)  ONS course: Safe Handling Basics  Clinical Journal of Oncology Nursing article: Safe Management of Chemotherapy in the Home  ONS Learning Library: Safe Handling of Hazardous Drugs  ONS Position Statement: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs  National Institute for Occupational Safety and Health article: Managing Hazardous Drug Exposures: Information for Healthcare Settings  NIOSH List of Hazardous Drugs in Healthcare Settings, 2024  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode  “So we look for a carcinogenic hazard. So does this molecule, does this chemical, this drug, have the ability to increase the risk of cancer? A lot of the time that will also tie with genotoxic hazards, but not always. There are some drugs on the list that are carcinogenic through other mechanisms. Sometimes carcinogenicity can be related to hormone signals, can lead to increased risk of cancer. There's some nuance there, but is it a carcinogenic hazard? That can get it onto the list. Is it a developmental and reproductive hazard?” TS 10:48  “NIOSH can't say what's right for every situation, but some organizations have suggested further precautions such as temporary alternative duty for workers who are pregnant or are looking to become pregnant. NIOSH can't say what's best for any given facility, but other organizations have given some good suggestions you may want to look into.” TS 13:18  “The list doesn't really rank hazard. I know a lot of people have kind of treated it that way a lot of times. We don't say that something is less hazardous if it's only a developmental or reproductive hazard, because if you're trying to have a child, then that's an important hazard to you. And we don't necessarily say something that's carcinogenic is more hazardous.” TS 14:34  “Some standard setting organizations have set standards for handling. Really in the oncology setting, particularly oncology pharmacy setting, it's really changed how some of the handling happens there because some of the standards come out of the pharmacy world. And what's happened there is some drugs that are oncology drugs, they might have been on table one before just because they were used in the treatment of cancer. They were antineoplastics, so they were on table one. Now, because they're not identified as a potential carcinogen and they don't have manufactured special handling information, they are now on table two.” TS 23:39  “Occasionally, if a drug comes out and has manufacturer special handling information, we'll go ahead and add it to the list. And since we won't add it into the publication, we typically have a table on that page that puts that there. If a drug is reevaluated and we find that the hazard is not as bad as expected or it's not a hazard, actually, and we can remove it from the list; sometimes we get new information and that happens.” TS 30:30 

The Stupid History of Chemotherapy Become a supporter of this podcast: https://www.spreaker.com/podcast/the-stupid-history-minute--4965707/support.

Joelle covers several steps of the cancer process in her book Crushing the Cancer Curveball. These include - prevention, diagnosis, treatment, surgery, and recovery. This is helpful for both the person dealing with cancer and the person who is showing support. With the high odds of developing cancer of any kind, the information Joelle presents is helpful for everyone.Joelle Kaufman's life has been shaped by breast cancer since age 13, culminating in her own 2023 diagnosis—the fourth in her immediate family. As CEO and Founder of GTM Flow, she combines cancer-forged resilience with cutting-edge go-to-market leadership strategies. Joelle's expertise spans healthcare and business, earning her positions on the UCSF Patient Experience Council and the Advisory Board of USC's The Pink Test. Her insights have been featured in the New York Times, Wall Street Journal, and Fortune Magazine. You can learn more at www.joellekaufman.com. Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

- Overview of Breast Cancer in Younger Women, Including Diagnosing, Staging & ER, PR, HER2 Status - Unique Issues for Younger Women Living with Breast Cancer - Precision Medicine & Sequencing of Treatment - Genetic Testing, Including BRCA Testing - What Informs Treatment Decisions & Options - Understanding Your Pathology Report - Updates on Clinical Trials: How Research Increases Treatment Options - Tools that Help Indicate What Types of Treatment Are Indicated: Surgery, Chemotherapy & Radiation Treatments - Questions to Ask Your Health Care Team - Managing Side Effects, Symptoms, Discomfort & Pain - Quality-of-Life, Including Sexual Health, Pregnancy & Fertility Issues - Practical & Emotional Coping Tips - Questions for Our Panel of Experts

- Overview of Breast Cancer in Younger Women, Including Diagnosing, Staging & ER, PR, HER2 Status - Unique Issues for Younger Women Living with Breast Cancer - Precision Medicine & Sequencing of Treatment - Genetic Testing, Including BRCA Testing - What Informs Treatment Decisions & Options - Understanding Your Pathology Report - Updates on Clinical Trials: How Research Increases Treatment Options - Tools that Help Indicate What Types of Treatment Are Indicated: Surgery, Chemotherapy & Radiation Treatments - Questions to Ask Your Health Care Team - Managing Side Effects, Symptoms, Discomfort & Pain - Quality-of-Life, Including Sexual Health, Pregnancy & Fertility Issues - Practical & Emotional Coping Tips - Questions for Our Panel of Experts

Can turmeric really help fight cancer? Can ancient wisdom actually support modern treatment? In this episode, I'm joined by Ayurvedic expert Dr. Shivani Gupta to explore the incredible healing potential of turmeric—and what every woman needs to know. Dr. Shivani Gupta and I dive deep into the science and tradition behind one of the most powerful natural anti-inflammatories on the planet: turmeric. We break down the truth about curcumin, the controversy surrounding its role in cancer treatment, and the critical role of absorption (yes, black pepper really matters).We also get real about:The disconnect between Western medicine and Eastern wisdomWhy adaptogens like Ashwagandha and Shilajit should be part of your routineHow to create simple, sustainable self-care rituals that workWhy women must be empowered to make their own treatment decisionsThis episode is a must-listen for anyone seeking a holistic approach to cancer, inflammation, and overall health.

Christ is your shelter when you are in the desert. -------- Thank you for listening! Your support of Joni and Friends helps make this show possible.     Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org   Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

In today's episode, supported by Takeda, we had the pleasure of speaking with Ibrahim T. Aldoss, MD, and Elias Jabbour, MD, about the use of ponatinib (Iclusig) monotherapy after combination chemotherapy in patients with newly diagnosed Philadelphia chromosome–positive (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Aldoss is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Drs Aldoss and Jabbour discussed findings from a post hoc subgroup analysis of the phase 3 PhALLCON trial (NCT03589326) that support the use of ponatinib monotherapy following combination treatment with a TKI plus chemotherapy in patients with newly diagnosed Ph-positive ALL, safety considerations when using ponatinib in this patient population, and how findings from this subgroup analysis may affect transplantation rates in this disease.

James Hible was 25 when he was diagnosed with testicular cancer. Twice, the same physician misdiagnosed his condition. After six months with a second lump plus a growing first lump on his testicle, James finally saw his regular doctor who sent him for a scan and immediately diagnosed testicular cancer. James had an orchiectomy and one round of chemotherapy to treat his Stage 1 testicular cancer and five years of surveillance that ended in 2020. Before, during, and now, after testicular cancer, James focused on his art. He was around seven years old when his family and teachers recognized his artistic talent. He liked to draw and continued with that passion into adulthood. However, James also discovered football at the same young age and enjoyed watching games then and now. He has collected more than 200 football shirts.Listen to James Hible in this episode of Don't Give Up on Testicular Cancer from the Max Mallory Foundation to hear an enlightening discussion about this young man's journey with testicular cancer.You can find out more about and see James Hible's illustrations on Instagram - https://www.instagram.com/hiblejames/Website - https://www.jameshible.com/Send us a textSupport the showFind us on Twitter, Instagram, Facebook & Linkedin. If you can please support our nonprofit through Patreon.

Anti-aging technologies - with Dr. Mike Van Thielen! -Highlights from the AAD -Vitamin D for toxic erythema of chemotherapy -Updates on the skin microbiome -Join Luke's CME experience on Jak inhibitors! rushu.gathered.com/invite/ELe31Enb69Want to donate to the cause? Do so here!
Donate to the podcast: uofuhealth.org/dermasphere
Check out our video content on YouTube:
www.youtube.com/@dermaspherepodcast
and VuMedi!: www.vumedi.com/channel/dermasphere/
The University of Utah's Dermatology
ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -
⁠ Connect with us!
- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn
more dermatology!

States rush to ban food dyes ahead of federal action; NIH cuts funds for studies of vaccine hesitancy; RFK Jr. ridiculed for urging vitamin A for measles; Brain tumors in firefighters show signature of chemical exposure; Unpacking the causes of numbness, tingling and pain in lower extremities; Class-action lawsuit targets Depo-Provera as contributor to meningioma brain tumors; Uncovering the mystery of Trump's 20+ pound weight loss; Microplastics implicated in spiraling antibiotic resistance.

In this episode with Peter Wilson we discuss the 13 calendar months, health, privacy, the corrupt officials and more #checkmatethematrix #matrix #peterwilsonAbout my Guest:Ex Royal Navy gunner and armourer, turned professional fighter. Owned and ran own martial arts gym for about 30 years. Always been aware of something not being right in the world, went deep into it after losing over £1million of property in 1 week including own home. So been up and been down even living in a car for a while with his wife Janine and 4 dogs. ---Awakening Podcast Social Media / Coaching My Other Podcasts  ⁠⁠⁠https://roycoughlan.com/⁠⁠ ------------------What we Discussed: 01:10 His Recent Event04:30 Oxygen Therapy07:20 Salt Therapy Room10:15 Water Vortex Machine13:35 Ozone Generator15:45 What was discussed about Crypto at the Event22:40 What is an Asset25:20 Gold and the French Warships going to the USA29:00 The FIAT Currency32:55 The 13 Month Calendar36:20 The Tides do not change41:40 Changing the Hrs twice yearly44:10 Protecting your Electronic Devices46:40 Cookies on the Internet49:15 There is No Privacy51:49 A lesson to Children about saying harsh words55:30 People are afraid to Support the People fighting the System57:30 People in Power Do Not Have Empathy1:00:15 City Officials treat you like Crap1:03:30 Is Your Job Helping Society or Hurting it1:03:50 GDPR to Help with Debt Collectors1:11:11 Holistic Dentistry1:18:04 Chemotherapy and Alternatives1:18:50 The Fog and how we can make change1:20:30 The Mouse in the Farmhouse StoryHow to Contact Peter:  https://www.claimyourstrawman.com/ https://checkmatethematrix.com/?linkId=lp_513119&sourceId=roy&tenantId=checkmate-the-matrixhttps://www.youtube.com/@ReturnToTrueDemocracy https://linktr.ee/PeterWilsonReturnToDemocracy https://www.linkedin.com/in/peter-wilson-a5a3872b/ ------------------------------All about Roy / Brain Gym & Virtual Assistants athttps://roycoughlan.com/------------------

Dr. Sue Yom, Editor in Chief, co-hosts with Dr. Lachlan McDowell, Consultant Radiation Oncologist at the Princess Alexandra Hospital in Queensland, Australia and our journal's Head and Neck Cancer Section Editor. Guests are Dr. Sean McBride, Radiation Oncologist at Memorial Sloan Kettering Cancer Center and Chief of External Beam Radiotherapy at the Manhattan site, who authored an editorial, Oligometastatic HNSCC: Is SABR the Solution?, and Dr. Juliette Thariat, Professor in Radiation Oncology at Cancer Center Baclesse in Normandy, France, Secrétaire Nationale at the GORTEC, and first author of our featured article, Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.

Dr. Kristen Lester has taken a unique journey as a general practitioner offering chemotherapy to dogs. Dr. Lester shares the inspiring cancer story of her "heart dog" Sue, the challenges of cancer treatment, and why she believes GPs can play a vital role in oncology. From safety protocols to overcoming the lack of local specialists, this episode is packed with insights for dog lovers and veterinarians alike.  What You'll Learn in This Episode:  How Dr. Lester got into oncology through her heart dog, Sue  The role general practitioners can play in cancer treatment  Safety protocols for administering chemo in a general practice  Tools and resources for GPs interested in oncology  The pros and cons of choosing a GP versus an oncologist  Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question.   Related Videos:  https://www.youtube.com/watch?v=PNbQ4mNx938  https://www.youtube.com/watch?v=V6_fWtQbxfw   Related Links:  This chemotherapy article covers EVERYTHING! https://www.dogcancer.com/articles/drugs/dog-chemotherapy/  Looking at metronomic chemo? Here's a great read: https://www.dogcancer.com/articles/diagnosis-and-medical-procedures/metronomic-chemotherapy-for-dogs/  Chapters:  00:00 Introduction  00:30 - Dr. Lester's Background: General Vet Meets Oncology  01:15 - The Heart Dog Who Started It All: Sue's Story  06:45 - What is Chemotherapy in General Practice Like?  08:30 - The Role of Palladia and Modern Cancer Drugs  12:15 - General Practitioners vs. Oncologists: Pros and Cons  19:00 - Safety Protocols for Chemo in General Practice  24:30 - Special Equipment Needed for Chemotherapy  30:15 - What Dog Owners Should Know About At-Home Chemo  35:00 - Common Cancers and Chemo Protocols GPs Can Handle  38:45 - How to Start Offering Chemo as a GP  45:15 - Resources and Support for General Practitioners  48:30 - Closing Thoughts: Fighting Cancer Together    Get to know Dr. Kristen Lester: https://www.dogcancer.com/people/kristen-marie-lester-dvm/  For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of Fat Science, Dr. Emily Cooper, Andrea Taylor and Mark Wright open the mailbag and answer questions from listeners all over the world.Dr. Cooper provides expert insights into complex questions about metabolic health, covering topics including metabolic dysfunction, the effects of chemotherapy on metabolism, a discussion of GLP-1s and those trying to get pregnant and the role of iodine in the diet. Engaging and informative, this episode also arms you with the vocabulary and understanding needed to discuss metabolism with your healthcare provider.Key Takeaways: Metabolic medications like GLP-1s are not just for weight loss; they target the metabolic system, improving fertility and metabolic health. The jury is still out as to whether taking GLP-1s are safe for those trying to become pregnant, but management is possible knowing the half-life of the various GLP-1 drugs. Chemotherapy can impact metabolism; a comprehensive metabolic assessment post-treatment is essential for recovery. Iodine is crucial for thyroid function, and deficiencies may arise from using non-iodized salts; checking iodine levels can guide supplementation. Managing mindset and mechanical eating is essential when using metabolic medications to avoid calorie-counting traps.Personal Stories & Practical Advice: Andrea shares her journey of freeing herself from calorie counting and embracing a healthier mindset. Listeners' questions reflect global engagement and common challenges faced in managing metabolic health.Resources: Connect with Dr. Emily Cooper on LinkedIn. Connect with Mark Wright on LinkedIn. Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org.Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study Editorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special Circumstances?

There is a moment when the body becomes foreign, when the timeline of your life no longer extends indefinitely but narrows into an unpredictable horizon. In this episode, Tara sits down with Michael Nagel, a beloved member of the AOA community, to speak candidly about what it means to love and be loved in the face of his cancer diagnosis. They discuss:The “psychedelic of mortality”—how the nearness of death transforms personal and social dynamicsEmbracing the support of a community while wrestling with the vulnerability of needing helpThe stark cost-benefit analysis of chemotherapyThe dual forces of grief and gratitude, and learning to hold both at onceDenial's strange and necessary role in maintaining the will to live.The radical act of saying yes to struggle, and what it means to want life even in its hardest momentsJoin us for a conversation that explores what it means to live when death is an ever-present companion.Send us your questions on Twitter, through our website, or in our Circle community! Joe on X: @FU_JoeHudson Brett on X: @airkistler AOA on X: @artofaccomp Visit Us: www.artofaccomplishment.com We invite you to experience our work. Reserve your spot at www.view.life/explore

Did you know that freezing your fish oil capsules can eliminate those dreadful fish burps? But that's just the tip of the iceberg. In this episode, we've collected your most burning questions about supplementation for post-chemotherapy, lifestyle recommendations for various illnesses or disorders, and addressing heavy metal exposure in the body. Optimising your health isn't just about following trends, it's about understanding the science behind what really works. Send in your questions for the next episode of The Ultimate Human Q&A, and together we'll uncover more biohacking and longevity solutions! Join Gary Brecka's FREE 3-Day Morning Routine Challenge!

Click here to receive today's free gift on the Radio Page: The Parable of the Prodigal Son – Enjoy compelling life applications and relevant lessons on grace, anger, and compassion. The Parable of the Prodigal Son tackles issues we all face today, and is perfect for new Christians wanting to study God's grace and forgiveness to all, and anyone needing a fresh reminder of the grace Christians are called to extend to all. Use the coupon code: RADIOGIFT for free shipping!*Limit one copy per person* --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

In this week's episode, we discuss the relationship between infectious and chronic disease, and between germ theory and terrain theory of disease. Pathogens are real, and exogenous treatments like antibiotics can kill them. The health of the body is affected by diet, exercise, stress, and the microbiome, all of which can affect how susceptible a person is to getting sick from pathogens. We discuss gastric ulcers, Covid-19, pneumococcal disease, and comorbidities. Also: how do traditional vs modern diets affect the health, dental and otherwise, of people? Why do pre-industrial people not get cavities, or need orthodontia? Why do squirrels fed by humans develop similarly malformed skulls as babies fed modern diets? Finally: do we have a responsibility to point out the carnage that will result as the Trump administration goes after decades of entrenched interests?*****Our sponsors:Caraway: Non-toxic, beautiful, light ceramic cookware. Save $150 on a cookware set over buying individual pieces, and get 10% off your order at http://carawayhome.com/DarkHorse.Manukora: the most flavorful, delicious, and nutritious honey you'll ever have. Get $25 off your starter kit at http://www.Manukora.com/DarkHorseARMRA Colostrum is an ancient bioactive whole food that can strengthen your immune system. Go to http://www.tryarmra.com/DARKHORSE to get 15% off your first order.Mentioned in this episode:*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:RFK Jr on chronic and infectious disease: https://x.com/ChildrensHD/status/1885018213701800387RFK Jr on The Real Anthony Fauci: https://amzn.to/40INnxF (commission earned)Marshall et al 1985. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust. 142:436–9:https://onlinelibrary.wiley.com/doi/abs/10.5694/j.1326-5377.1985.tb113443.xEvolutionary Lens Livestream #88 – w discussion of Covid x comorbidities: https://www.youtube.com/watch?v=KSWu6DUFFt4&t=337sHanada et al 2021. Multiple comorbidities increase the risk of death from invasive pneumococcal disease under the age of 65 years. Journal of Infection and Chemotherapy, 27(9): 1311-1318: https://www.sciencedirect.com/science/article/abs/pii/S1341321X21001252Nutrition and Physical Degeneration, by Weston Price (1939): https://amzn.to/4jXciXl (commission earned)Chandler et al 2025. Morphological change in an isolated population of red squirrels (Sciurus vulgaris) in Britain. Royal Society Open Science, 12(1): 240555.https://royalsocietypublishing.org/doi/10.1098/rsos.240555Support the show